Stage Migration in Urological Cancers in Germany during the COVID-19 Pandemic: Fact or Fiction?

IF 1.5 4区医学 Q3 UROLOGY & NEPHROLOGY

Urologia Internationalis Pub Date : 2025-02-25 DOI:10.1159/000544745

Henning Bahlburg, Patricia Rausch, Matteo Silberg, Karl Heinrich Tully, Sebastian Berg, Joachim Noldus, Marius Cristian Butea-Bocu, Burkhard Beyer, Guido Müller

{"title":"Stage Migration in Urological Cancers in Germany during the COVID-19 Pandemic: Fact or Fiction?","authors":"Henning Bahlburg, Patricia Rausch, Matteo Silberg, Karl Heinrich Tully, Sebastian Berg, Joachim Noldus, Marius Cristian Butea-Bocu, Burkhard Beyer, Guido Müller","doi":"10.1159/000544745","DOIUrl":null,"url":null,"abstract":"Introduction: The COVID-19 pandemic interrupted many aspects of health care, including cancer treatment. This study aims to assess the potential impact of the COVID-19 pandemic on tumor stage migration in the three most common urological malignancies.Methods: Patient and tumor characteristics of patients undergoing inpatient rehabilitation (IR) in one dedicated IR center in 2019 (pre-pandemic) and 2021 (mid-pandemic) were retrospectively evaluated. The study focused on patients after radical prostatectomy (RP) for prostate cancer (PCa), radical cystectomy (RC) for bladder cancer (BCa), or (partial) nephrectomy for kidney cancer (KC).Results: Overall, 9,039 patients (6,898 (76.3%) after RP, 1,427 (15.8%) after RC, 714 (7.9%) after (partial) nephrectomy) were enrolled. A significant decrease of PCa patients suffering from Gleason sum score ≥8 (17.6% vs. 20.5%, p = 0.005) and lymph node metastases (10.9% vs. 13.0%; p = 0.012) was observed. In BCa and KC patients, tumor stage distribution and abundance of lymph node metastases remained stable, while significantly more BCa patients received neoadjuvant chemotherapy (10.4% vs. 20.2%, p = 0.001). Overall, a significant increase in robot-assisted surgery across all investigated malignancies was detected.Conclusions: No stage migration could be detected across the three most common urological malignancies during the COVID-19 pandemic. Therapeutic standards remained high, while oncological outcomes remained relatively unchanged.","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-7"},"PeriodicalIF":1.5000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Internationalis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000544745","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The COVID-19 pandemic interrupted many aspects of health care, including cancer treatment. This study aims to assess the potential impact of the COVID-19 pandemic on tumor stage migration in the three most common urological malignancies.

Methods: Patient and tumor characteristics of patients undergoing inpatient rehabilitation (IR) in one dedicated IR center in 2019 (pre-pandemic) and 2021 (mid-pandemic) were retrospectively evaluated. The study focused on patients after radical prostatectomy (RP) for prostate cancer (PCa), radical cystectomy (RC) for bladder cancer (BCa), or (partial) nephrectomy for kidney cancer (KC).

Results: Overall, 9,039 patients (6,898 (76.3%) after RP, 1,427 (15.8%) after RC, 714 (7.9%) after (partial) nephrectomy) were enrolled. A significant decrease of PCa patients suffering from Gleason sum score ≥8 (17.6% vs. 20.5%, p = 0.005) and lymph node metastases (10.9% vs. 13.0%; p = 0.012) was observed. In BCa and KC patients, tumor stage distribution and abundance of lymph node metastases remained stable, while significantly more BCa patients received neoadjuvant chemotherapy (10.4% vs. 20.2%, p = 0.001). Overall, a significant increase in robot-assisted surgery across all investigated malignancies was detected.

Conclusions: No stage migration could be detected across the three most common urological malignancies during the COVID-19 pandemic. Therapeutic standards remained high, while oncological outcomes remained relatively unchanged.

查看原文本刊更多论文

COVID-19大流行期间德国泌尿系统癌症的阶段迁移：事实还是虚构？

背景：2019冠状病毒病大流行中断了包括癌症治疗在内的许多卫生保健方面。本研究旨在评估COVID-19大流行对三种最常见的泌尿系统恶性肿瘤分期迁移的潜在影响。方法：回顾性评价2019年（大流行前）和2021年（大流行中期）在一个专门的IR中心接受住院康复（IR）患者的患者和肿瘤特征。本研究主要针对前列腺癌（PCa）根治性前列腺切除术（RP）、膀胱癌（BCa）根治性膀胱切除术（RC）或肾癌（KC）（部分）肾切除术后的患者。结果共纳入9039例患者，其中RP术后6898例（76.3%），RC术后1427例（15.8%），部分肾切除术后714例（7.9%）。Gleason sum评分≥8的前列腺癌患者（17.6% vs. 20.5%, p=0.005）和淋巴结转移(10.9% vs. 13.0%；P =0.012)。在BCa和KC患者中，肿瘤分期分布和淋巴结转移丰度保持稳定，而BCa患者接受新辅助化疗的比例明显更高（10.4%比20.2%,p=0.001）。总体而言，在所有被调查的恶性肿瘤中检测到机器人辅助手术的显着增加。结论：在COVID-19大流行期间，三种最常见的泌尿系统恶性肿瘤未检测到分期转移。治疗标准仍然很高，而肿瘤结果保持相对不变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Urologia Internationalis 医学-泌尿学与肾脏学

CiteScore

3.30

自引率

6.20%

发文量

审稿时长

3-8 weeks

期刊介绍： Concise but fully substantiated international reports of clinically oriented research into science and current management of urogenital disorders form the nucleus of original as well as basic research papers. These are supplemented by up-to-date reviews by international experts on the state-of-the-art of key topics of clinical urological practice. Essential topics receiving regular coverage include the introduction of new techniques and instrumentation as well as the evaluation of new functional tests and diagnostic methods. Special attention is given to advances in surgical techniques and clinical oncology. The regular publication of selected case reports represents the great variation in urological disease and illustrates treatment solutions in singular cases.